Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.
You may also be interested in...
Biosimilar Cost Savings In Europe Beyond 25% Might Cull Sponsors, EGA Warned
Trade association hears pricing discipline and differentiated products are keys to sustaining European biosimilars market even as it continues to grow.
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.